Incyte Corporation has announced a significant investment of $1.25 billion to acquire Vega Therapeutics, a startup focused on developing a novel treatment for severe von Willebrand disease, a bleeding disorder. This acquisition aims to introduce a candidate drug that promises a more convenient dosing schedule for patients, potentially setting a new standard of care in the field. With Incyte’s flagship product facing impending patent expiration, the acquisition will also diversify its pipeline targeting blood disorders.<\/p>\n
Vega Therapeutics represents Incyte\u2019s first acquisition under newly appointed CEO Bill Meury, who succeeded long-time leader Herv\u00e9 Hoppenot last year. During a conference call, Meury emphasized Vega\u2019s strong clinical data, clear regulatory pathway, and promising commercial opportunities as key factors in the decision to pursue the acquisition.<\/p>\n
\u201cVGA039 meets all our criteria for a commercial development opportunity,\u201d Meury stated. \u201cIt aligns perfectly with our core focus in hematology, where we have substantial expertise in the science, disease, R&D, and business operational models.\u201d<\/p>\n
Von Willebrand disease is characterized by a deficiency or dysfunction of the von Willebrand factor, a crucial protein in blood coagulation. According to the Centers for Disease Control and Prevention, it affects about 1% of the U.S. population, translating to approximately 3.2 million individuals, making it the most common inherited bleeding disorder. Patients often experience frequent and severe bleeding episodes.<\/p>\n
For those whose condition does not adequately respond to desmopressin, a hormone that helps release the von Willebrand factor, regular infusions of this protein are the next treatment option. While several plasma-derived versions exist, including Takeda Pharmaceutical\u2019s Vonvendi, which is the only FDA-approved treatment, patients must endure intravenous infusions up to three times a week\u2014amounting to as many as 156 treatments per year.<\/p>\n
In contrast, VGA039 offers the potential for monthly subcutaneous dosing that patients can self-administer. This monoclonal antibody targets a new protein, known as protein S (ProS), involved in pathways that prevent excessive clotting. By inhibiting ProS, VGA039 aims to restore protein balance in blood coagulation. According to Vega, von Willebrand disease is the inaugural application among several potential uses for this drug in coagulation disorders.<\/p>\n
In a Phase 1\/2 open-label study, VGA039 demonstrated a clinically significant reduction of 74% in bleeding rates, with all dosages proving safe and well-tolerated. These findings were presented at last year\u2019s American Society of Hematology (ASH) annual meeting. Currently, an open-label Phase 3 trial is underway, assessing the drug’s efficacy in preventing bleeding across all types of von Willebrand disease in patients aged 12 to 75. Preliminary results are expected by early 2029.<\/p>\n
Incyte’s strategy centers on treating the most severe forms of von Willebrand disease. Despite the CDC’s reported high prevalence, only about 135,000 Americans have been formally diagnosed. Of approximately 35,000 patients seeking specialized treatment, 7,000 to 10,000 experience significant bleeding episodes, qualifying them for prophylaxis, although only around 2,000 actually receive these preventive treatments, as noted by Incyte’s strategy director, Dave Gardner.<\/p>\n
Incyte aims to broaden the prophylactic market for von Willebrand disease with a more user-friendly treatment paradigm. This approach echoes previous success in hemophilia A, where Roche’s Hemlibra has gained traction as a subcutaneous therapy, offering a less burdensome alternative to regular factor infusions since its 2017 approval.<\/p>\n
“History shows that as prophylactic options become more convenient, patient adoption rates can soar to around 90%, compared to the current 25% for severe or recurrent von Willebrand disease,” Gardner explained. \u201cThis highlights the tangible opportunity to close the gap between those needing prophylaxis and those receiving it.\u201d<\/p>\n
VGA039 was discovered and developed by Vega, a subsidiary of Star Therapeutics. Star operates a \u201cstar\u201d model, creating startups focused on specific drug programs that can leverage shared resources while independently advancing their candidates. Vega launched in 2022, presenting initial preclinical data at ASH 2022.<\/p>\n
Incyte is well established in hematology, with four marketed medications and additional candidates in its pipeline. Jakafi, the company’s leading hematology drug, generated $3 billion in revenue last year, marking over a 10% increase from the previous year. However, as the Jakafi patent expires in 2028, Incyte is keen on fostering new revenue drivers.<\/p>\n
In a recent investor presentation, Incyte projected that VGA039 could produce over $1 billion in net global sales. However, competition looms from Hemab Therapeutics, which has advanced its pipeline including the prophylactic treatment HMB-002, currently in Phase 2 trials for von Willebrand disease. Analyst Matt Phipps from William Blair highlights Vega’s acquisition as a strategic fit for Incyte’s hematology portfolio, providing a relatively low-risk candidate with significant sales potential.<\/p>\n
Phipps noted, \u201cWhile the ongoing Phase 3 study results are anticipated for early 2029, leading to a possible launch in 2030\u2014just after Jakafi\u2019s loss of exclusivity\u2014this acquisition enhances Incyte’s growth outlook for the decade ahead.\u201d<\/p>\n
The $1.25 billion deal includes an initial payment, with potential additional payments of up to $750 million contingent on hitting sales milestones. Both companies expect to finalize the transaction during Q3 of this year. As of the end of Q1, Incyte reported strong cash reserves of $4 billion, and Meury confirmed the company remains positioned to pursue further transactions as opportunities arise.<\/p>\n
\u201cWe are patient at this moment,\u201d he stated. \u201cIf we see something that makes sense, we will act. Otherwise, we will wait.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
Incyte Corporation has announced a significant investment of $1.25 billion to acquire Vega Therapeutics, a…<\/p>\n","protected":false},"author":1,"featured_media":1956,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[19],"tags":[],"class_list":["post-1955","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma"],"_links":{"self":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/comments?post=1955"}],"version-history":[{"count":1,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1955\/revisions"}],"predecessor-version":[{"id":1957,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1955\/revisions\/1957"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media\/1956"}],"wp:attachment":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media?parent=1955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/categories?post=1955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/tags?post=1955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}